text: Inhibitors Inhibitors have been designed with the aim of developing analgesic and antihypertensive agents that act by preventing neprilysin's activity against signaling peptides such as enkephalins, substance P, endothelin, and atrial natriuretic peptide.
  Some are intended to treat heart failure.
  Sacubitril/valsartan (Entresto/LCZ696), which has been tested against enalapril in patients with heart failure.
  Sacubitril (AHU-377), a prodrug which is a component of sacubitril/valsartan
  Sacubitrilat (LBQ657), the active form of sacubitril
  RB-101, an enkephalinase inhibitor, used in scientific research.
  UK-414,495
  Omapatrilat (dual inhibitor of NEP and angiotensin-converting enzyme) developed by BMS did not receive FDA approval due to angioedema safety concerns.
  Ecadotril
  Candoxatril
  Other dual inhibitors of NEP with ACE/angiotensin receptor were (in 2003) being developed by pharmaceutical companies.
  Immunochemistry
  CD10 is used in clinical pathology for diagnostic purpose.
  In lymphomas and leukemias
  Acute lymphoblastic leukemia (ALL) cells are CD10+.
  Follicular lymphoma (follicle centre cell lymphoma) are CD10+.
  Burkitt Lymphoma cells are CD10+.
  CD10+ diffuse large B cell lymphoma (CD10+ DLBCL)
  Marker for germinal center phenotype (CD10, HGAL, BCL6, CD38) are considered a favorable prognostic factor, but CD10+, BCL2+ tumors could have poorer survival. For some authors, CD10 expression in DLBCL does not influence survival.
  Angioimmunoblastic T cell lymphoma (AITL) are CD10+ and distinguishes AITL from other T cell lymphomas (CD10−)